Opinion|Videos|March 15, 2024

Key Takeaways on Zanubrutinib Data

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Mazyar Shadman, MD, MPH

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.

Episodes in this series

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 1 SEQUOIA: Zanubrutinib vs BR in First-Line CLL/SLL

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 2 ALPINE: Zanubrutinib or Ibrutinib in Relapsed/Refractory CLL

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 3 Efficacy of Zanubrutinib vs Acalabrutinib in R/R CLL: A Matching-Adjusted Indirect Comparison

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 4 Zanubrutinib Safety Profile in CLL

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 5 Key Takeaways on Zanubrutinib Data

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Choosing CLL Therapy Around Molecular Risk, Comorbidities, and Patient Preference

October 22nd, 2026

Choosing CLL Therapy Around Molecular Risk, Comorbidities, and Patient Preference

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

Trending on Targeted Onc

ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care

Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026

ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care

340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent

Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC